New Biomarker and Comorbidity Insights in NMOSD and MOGAD
Professor Nasrin Asgari shared updates at ECTRIMS 2024 on Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). He highlighting a potential new CNS protein biomarker, MFAP4, which may aid in predicting relapses. Additionally, studies on comorbidities show that over 50% of patients have at least one comorbidity, and 30% have multimorbidity, complicating treatment and worsening outcomes. Routine screening for these conditions is suggested to improve diagnosis and patient care.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in